as group then treated human and mouse liver cancer cell lines with a monoclonal antibody targeted against PDGFR alpha. It resulted in a significant decrease in tumor cell proliferation and a marked increase in tumor cell death.
In fact, all tumor cell lines experienced significant decreases in proliferation in response to the monoclonal antibody and there was a 4- to 18-fold increase in programmed cell death, or apoptosis, among the cancer cell lines compared to normal control cells.
According to Dr. Monga, these results suggest that PDGFR alpha offers an important new therapeutic target for the treatment of HCC.
We are very excited because this is the first targeted therapy for liver cancer. Other therapies have some modest benefits, but no one knows exactly how they work.
We now have identified a pathway that appears to be overly active in more than 70 percent of the cancers we examined and, when targeted, leads to significant reduction in tumor cell proliferation and survival, said Dr. Monga.
More importantly, targeting the PDGFR pathway in liver cancer cells does not appear to affect normal liver cells, making the treatment relatively non-toxic.
Normally, regenerating liver cells are not exclusively dependent on this pathway, and it is not overly active in other types of cells. So this monoclonal antibody is a highly targeted treatment for this disease, he added.
Furthermore, because high expression of PDGFR alpha has been detected in a variety of tumors, such as skin cancer, brain tumors, gastrointestinal tumors, prostate tumors, ovarian cancer and leukemia, Dr. Monga believes these findings could have much broader applications.
'"/>Page: 1 2 Related medicine news :1.
Therapeutic Monoclonal Antibody Production Is More Profitable Than Small Molecule Drugs2.
Monoclonal antibodies show promise in treatment of blood cancer3.
Monoclonal Anti-Body To Revolutionize Brain Cancer Treatment4.
Monoclonal Antibody based system for Anthrax detection5.
Monoclonal Antibody Reduces Exacerbations in Asthmatics6.
Survival of Mice With Human Breast Cancer Extended by Monoclonal Antibodies7.
Monoclonal Antibody Induces Death in Liver Cancer Cells8.
Human Antibody That Can Block SARS9.
Cuba Registers New Antibody10.
Single Sugar Enables Antibody to Treat Inflammation11.
Anti-rejection Therapy a Boon for Patients With "anti-donor" Antibody Levels